Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page
- Check3 days agoChange DetectedAdded the disease category Squamous cell carcinoma of the head and neck and introduced a Resources section linking the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.5.0 was added and v3.4.3 was removed. The update does not modify study details or user-facing content.SummaryDifference0.1%

- Check25 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3; no visible content changes on the page.SummaryDifference0.1%

- Check53 days agoChange DetectedPage updated to Revision: v3.4.2 and the government funding status notice was removed; no study content or eligibility criteria were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check60 days agoChange DetectedAdded a site-wide status notice about a lapse in government funding and the NIH Clinical Center’s operations, and updated the site version to v3.4.1, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check67 days agoChange DetectedNew UI elements were added: a glossary toggle, a 'Last Update Submitted that Met QC Criteria' entry, a 'No FEAR Act Data' notice, and a revision tag showing v3.4.0. The prior items—'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and revision v3.3.4—were removed.SummaryDifference0.2%

Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.